Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Clinical trial NCT04666259 · COMPLETED
Trial details
- NCT number
- NCT04666259
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-25
- Primary completion
- 2023-06-20
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.